These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
621 related articles for article (PubMed ID: 29426004)
1. Cell membrane-coated nanocarriers: the emerging targeted delivery system for cancer theranostics. Bose RJ; Paulmurugan R; Moon J; Lee SH; Park H Drug Discov Today; 2018 Apr; 23(4):891-899. PubMed ID: 29426004 [TBL] [Abstract][Full Text] [Related]
2. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics. Zhang W; Liu M; Liu A; Zhai G Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244 [TBL] [Abstract][Full Text] [Related]
3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
4. Transvascular transport of nanocarriers for tumor delivery. Li X; Hu Y; Zhang X; Shi X; Parak WJ; Pich A Nat Commun; 2024 Sep; 15(1):8172. PubMed ID: 39289401 [TBL] [Abstract][Full Text] [Related]
5. Hybrid protein-inorganic nanoparticles: From tumor-targeted drug delivery to cancer imaging. Elzoghby AO; Hemasa AL; Freag MS J Control Release; 2016 Dec; 243():303-322. PubMed ID: 27794493 [TBL] [Abstract][Full Text] [Related]
6. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. Attia MF; Anton N; Wallyn J; Omran Z; Vandamme TF J Pharm Pharmacol; 2019 Aug; 71(8):1185-1198. PubMed ID: 31049986 [TBL] [Abstract][Full Text] [Related]
7. From The Mine to Cancer Therapy: Natural and Biodegradable Theranostic Silicon Nanocarriers from Diatoms for Sustained Delivery of Chemotherapeutics. Maher S; Kumeria T; Wang Y; Kaur G; Fathalla D; Fetih G; Santos A; Habib F; Evdokiou A; Losic D Adv Healthc Mater; 2016 Oct; 5(20):2667-2678. PubMed ID: 27594524 [TBL] [Abstract][Full Text] [Related]
8. Cell membrane-coated nanosized active targeted drug delivery systems homing to tumor cells: A review. He Z; Zhang Y; Feng N Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110298. PubMed ID: 31753336 [TBL] [Abstract][Full Text] [Related]
9. Hybrid quantum dot-based theranostic nanomedicines for tumor-targeted drug delivery and cancer imaging. Zayed DG; AbdElhamid AS; Freag MS; Elzoghby AO Nanomedicine (Lond); 2019 Feb; 14(3):225-228. PubMed ID: 30652951 [No Abstract] [Full Text] [Related]
10. Calcium phosphate nanocarriers for drug delivery to tumors: imaging, therapy and theranostics. Huang D; He B; Mi P Biomater Sci; 2019 Oct; 7(10):3942-3960. PubMed ID: 31414096 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in aptamer-armed multimodal theranostic nanosystems for imaging and targeted therapy of cancer. Vandghanooni S; Eskandani M; Barar J; Omidi Y Eur J Pharm Sci; 2018 May; 117():301-312. PubMed ID: 29499349 [TBL] [Abstract][Full Text] [Related]
12. Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery. Xie Z; Su Y; Kim GB; Selvi E; Ma C; Aragon-Sanabria V; Hsieh JT; Dong C; Yang J Small; 2017 Mar; 13(10):. PubMed ID: 28026115 [TBL] [Abstract][Full Text] [Related]
13. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723 [TBL] [Abstract][Full Text] [Related]
14. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities. Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer. Thorat ND; Townley HE; Patil RM; Tofail SAM; Bauer J Drug Discov Today; 2020 Jul; 25(7):1245-1252. PubMed ID: 32371139 [TBL] [Abstract][Full Text] [Related]
17. A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents. [Corrected]. Wang H; Agarwal P; Zhao S; Yu J; Lu X; He X Nat Commun; 2015 Dec; 6():10081. PubMed ID: 26621191 [TBL] [Abstract][Full Text] [Related]
18. Prussian blue nanoparticles and their analogues for application to cancer theranostics. Patra CR Nanomedicine (Lond); 2016 Mar; 11(6):569-72. PubMed ID: 26911239 [No Abstract] [Full Text] [Related]
19. Advances in refunctionalization of erythrocyte-based nanomedicine for enhancing cancer-targeted drug delivery. Sun D; Chen J; Wang Y; Ji H; Peng R; Jin L; Wu W Theranostics; 2019; 9(23):6885-6900. PubMed ID: 31660075 [TBL] [Abstract][Full Text] [Related]
20. Nanocarriers for cancer-targeted drug delivery. Kumari P; Ghosh B; Biswas S J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]